20CM涨停热景生物：生物创新药及肿瘤早筛等相关业务由联营企业独立运营

Core Viewpoint - The company Hotgen Biotech (688068.SH) has announced that its main business involves the research, production, and sales of in vitro diagnostic reagents and related instruments, while its biopharmaceutical innovation and early cancer screening businesses are independently operated by joint ventures [1] Group 1 - The main business of Hotgen Biotech is focused on in vitro diagnostic reagents and related instruments [1] - The biopharmaceutical innovation and early cancer screening businesses are managed by joint ventures including ShunJing Pharmaceutical, YaoJing Genetics, ZhiYuan Biotech, and AoRui Biotech [1] - The related businesses are characterized by high research and development investment and significant research risks [1]